TaiGen teams up with Luminarie to tap into N AmericaBy Kao Shih-ching / Staff reporterTaiGen Biopharmaceuticals Holdings Ltd (太景醫藥研發控股) on Wednesday said that it is venturing into the North American market through its partnership with Luminarie Canada Inc, which would develop and commercialize its antibiotic Taigexyn in Canada. Photo: Chen Yung-chi, Taipei TimesLuminarie would purchase Taigexyn at a pre-negotiated price from TaiGen for its commercialization, it said. TaiGen also licensed Luminarie to seek another company that would commercialize Taigexyn in the US, to leverage the Canadian pharmaceutical company’s network in North America, it said. “We are interested in Luminarie because we share the same innovative vision for Taigexyn,” TaiGen chairman Philip Huang (黃國龍) said in a statement. Through the partnership with Luminarie, TaiGen has expanded the drug into 35 markets, including Taiwan and China, said the official, who declined to be named.

Source: Taipei Times October 01, 2020 15:56 UTC